Analyst Josh Jennings from TD Cowen maintained a Hold rating on Becton Dickinson and keeping the price target at $183.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Josh Jennings has given his Hold rating due to a combination of factors related to Becton Dickinson’s recent financial performance and future guidance. The company’s fourth-quarter sales of $5.9 billion aligned with market expectations, and its earnings per share (EPS) of $3.96 exceeded forecasts. However, the guidance for fiscal 2026 indicates low single-digit sales growth, factoring in significant headwinds from various segments, including Alaris, China, and Pharm Systems vaccines.
Despite the positive EPS performance, the guidance for the first quarter of the next fiscal year suggests both sales and EPS may fall short of market expectations. While certain segments like BD Medical and Interventional showed robust growth, others such as Biosciences faced challenges. The mixed results across different divisions and the cautious future outlook contribute to the Hold rating, indicating that while the company is stable, significant upside potential may be limited in the near term.
In another report released on November 3, Bank of America Securities also maintained a Hold rating on the stock with a $190.00 price target.